Kimberly L. Johung, MD, PhD
Cards
Appointments
Titles
Vice Chair for Education, Therapeutic Radiology; Director of Residency Training Program, Therapeutic Radiology; Chief, Gastrointestinal Radiotherapy Program, Therapeutic Radiology; Chief, VA Radiotherapy Program, Therapeutic Radiology
Contact Info
Therapeutic Radiology
P. O. Box 208040
New Haven, CT 06520-8040
United States
Appointments
Titles
Vice Chair for Education, Therapeutic Radiology; Director of Residency Training Program, Therapeutic Radiology; Chief, Gastrointestinal Radiotherapy Program, Therapeutic Radiology; Chief, VA Radiotherapy Program, Therapeutic Radiology
Contact Info
Therapeutic Radiology
P. O. Box 208040
New Haven, CT 06520-8040
United States
Appointments
Titles
Vice Chair for Education, Therapeutic Radiology; Director of Residency Training Program, Therapeutic Radiology; Chief, Gastrointestinal Radiotherapy Program, Therapeutic Radiology; Chief, VA Radiotherapy Program, Therapeutic Radiology
Contact Info
Therapeutic Radiology
P. O. Box 208040
New Haven, CT 06520-8040
United States
About
Titles
Associate Professor of Therapeutic Radiology
Vice Chair for Education, Therapeutic Radiology; Director of Residency Training Program, Therapeutic Radiology; Chief, Gastrointestinal Radiotherapy Program, Therapeutic Radiology; Chief, VA Radiotherapy Program, Therapeutic RadiologyBiography
Gastrointestinal cancers, including esophageal, gastric, pancreatic, hepatic, rectal, and anal cancers
Stereotactic body radiotherapy (SBRT) for tumors of the chest and abdomen
Lung cancer, head and neck cancer, prostate cancer
Appointments
Therapeutic Radiology
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- Residency
- Yale-New Haven Hospital (2013)
- Internship
- Yale-New Haven Hospital (2009)
- MD
- Yale University School of Medicine (2008)
- PhD
- Yale University (2007)
- BA
- Yale University (1999)
Research
Research at a Glance
Yale Co-Authors
Publications Timeline
Henry S. Park, MD, MPH
Jeremy Kortmansky, MD
Jill Lacy, MD
Michael Cecchini, MD
Stacey Stein, MD
Suzanne B. Evans, MD, MPH, FASTRO
Publications
2024
Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer
Cecchini M, Salem R, Robert M, Czerniak S, Blaha O, Zelterman D, Rajaei M, Townsend J, Cai G, Chowdhury S, Yugawa D, Tseng R, Arbelaez C, Jiao J, Shroyer K, Thumar J, Kortmansky J, Zaheer W, Fischbach N, Persico J, Stein S, Khan S, Cha C, Billingsley K, Kunstman J, Johung K, Wiess C, Muzumdar M, Spickard E, Aushev V, Laliotis G, Jurdi A, Liu M, Escobar-Hoyos L, Lacy J. Perioperative Modified FOLFIRINOX for Resectable Pancreatic Cancer. JAMA Oncology 2024, 10 PMID: 38900452, PMCID: PMC11190830, DOI: 10.1001/jamaoncol.2024.1575.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression-free survivalPancreatic ductal adenocarcinomaOverall survivalCtDNA levelsPhase 2 nonrandomized controlled trialAnalysis of circulating tumor DNAMedian progression-free survivalResectable pancreatic ductal adenocarcinomaControlled trialsAssess surgical candidacyBaseline ctDNA levelModified 5-fluorouracilResectable pancreatic cancerPancreatic protocol computed tomographyAssociated with recurrenceTumor molecular featuresAggressive malignant tumorKaplan-Meier estimatesRandomized clinical trialsStandard of careCtDNA-positivePreoperative cyclesNonrandomized controlled trialsUnresectable diseaseModified FOLFIRINOXColon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.
Benson A, Venook A, Adam M, Chang G, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Haste P, Hecht J, Hoffe S, Hunt S, Hussan H, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Malla M, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Shogan B, Skibber J, Sofocleous C, Tavakkoli A, Willett C, Wu C, Gurski L, Snedeker J, Jones F. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2024, 22 PMID: 38862008, DOI: 10.6004/jnccn.2024.0029.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsMetastatic colorectal cancerColorectal cancerNCCN Clinical Practice GuidelinesSystemic therapy optionsGoal of therapyClinical practice guidelinesNCCN GuidelinesToxicity profileTherapy optionsColon cancerMutation profilesActive drugCancer deathDiagnosed cancerCancerConstituent drugsTherapyPractice guidelinesNCCNDrugTumorColorectalGuidelinesUnited StatesOncologyA single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer
Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, Stein S, Cheng Y, Lam W, Liu S, Reddy V, Hochster H, Higgins S. A single arm phase 2 clinical trial of YIV-906 with neoadjuvant concurrent chemo-radiation therapy in patients with locally advanced rectal cancer. Journal Of Gastrointestinal Oncology 2024, 15: 1050-1059. PMID: 38989411, PMCID: PMC11231844, DOI: 10.21037/jgo-24-23.Peer-Reviewed Original Research
2023
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
Cecchini M, Zhang J, Wei W, Sklar J, Lacy J, Zhong M, Kong Y, Zhao H, DiPalermo J, Devine L, Stein S, Kortmansky J, Johung K, Bindra R, LoRusso P, Schalper K. Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer. Cancer Research Communications 2023, 3: 1132-1139. PMID: 37387791, PMCID: PMC10305782, DOI: 10.1158/2767-9764.crc-23-0045.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsWhole-exome sequencingMGMT protein expressionColorectal cancerStable diseaseQuantitative immunofluorescenceT cellsProtein expressionPromoter hypermethylationLow MGMT protein expressionPARP inhibitorsRadiographic tumor regressionMetastatic colorectal cancerAdvanced colorectal cancerPretreatment tumor biopsiesEffector T cellsTumor-infiltrating lymphocytesMGMT proteinDNA repair biomarkersBaseline CD8Eligible patientsIncreased CD8Methylguanine-DNA methyltransferaseObjective responseProgressive diseaseImmune markersAnal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
Benson A, Venook A, Al-Hawary M, Azad N, Chen Y, Ciombor K, Cohen S, Cooper H, Deming D, Garrido-Laguna I, Grem J, Hecht J, Hoffe S, Hubbard J, Hunt S, Hussan H, Jeck W, Johung K, Joseph N, Kirilcuk N, Krishnamurthi S, Maratt J, Messersmith W, Meyerhardt J, Miller E, Mulcahy M, Nurkin S, Overman M, Parikh A, Patel H, Pedersen K, Saltz L, Schneider C, Shibata D, Skibber J, Sofocleous C, Stotsky-Himelfarb E, Tavakkoli A, Willett C, Williams G, Algieri F, Gurski L, Stehman K. Anal Carcinoma, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology. Journal Of The National Comprehensive Cancer Network 2023, 21: 653-677. PMID: 37308125, DOI: 10.6004/jnccn.2023.0030.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNCCN Clinical Practice GuidelinesAnal carcinomaClinical practice guidelinesPrimary treatmentPractice guidelinesSquamous cell anal carcinomaCommon histologic formExtrapelvic metastatic diseaseMetastatic anal carcinomaSystemic therapy recommendationsAnal canal cancerCurative-intent treatmentAJCC staging systemNCCN guidelinesPerianal cancerMetastatic diseasePersistent diseaseSystemic therapySurgical treatmentMedical oncologyStaging systemOptimal treatmentClinical evaluationHistologic formsTherapy recommendationsPre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer
Peters G, Talcott W, Peters N, Dhanasopan A, Lacy J, Cecchini M, Kortmansky J, Stein S, Lattanzi S, Park H, Boffa D, Johung K, Jethwa K. Pre-operative chemoradiotherapy with or without induction chemotherapy for operable locally-advanced esophageal cancer. Journal Of Gastrointestinal Oncology 2023, 14: 1181-1192. PMID: 37435226, PMCID: PMC10331751, DOI: 10.21037/jgo-22-1005.Peer-Reviewed Original ResearchCitationsAltmetricConceptsProgression-free survivalMedian progression-free survivalOverall survivalIC-CRTInduction chemotherapySingle-institution retrospective cohort studyPre-operative chemoradiotherapyAdvanced esophageal cancerAdvanced esophageal carcinomaPathologic complete responseRetrospective cohort studyKaplan-Meier methodSubset of patientsProportional hazards regressionCycles of inductionAdenocarcinoma histologyCRT cohortCohort studyComplete responsePathologic responseTreatment cohortsDistant metastasisHazards regressionEsophageal cancerEsophageal carcinoma
2022
Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Johung K, Boffa D. Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer. JTO Clinical And Research Reports 2022, 3: 100429. PMID: 36483656, PMCID: PMC9722471, DOI: 10.1016/j.jtocrr.2022.100429.Peer-Reviewed Original ResearchCitationsConceptsStage IV esophageal cancerNational Cancer DatabaseEsophageal cancerCancer DatabaseRadiation doseSurvival advantageMedian total radiation dosePropensity score-matched pairsOutcome of radiationRetrospective cohort studyKaplan-Meier analysisTotal radiation doseAppropriate radiation dosePalliative regimensCohort studyMedian ageRadiation administrationSurvival associationsBetter survivalPatientsLocal controlCancerDosePalliationFurther studiesDosimetric Parameters are Associated with Local Control after SBRT for Colorectal Cancer Lung Metastases
Laird J, Mokhtech M, Johung K, Park H, Jethwa K. Dosimetric Parameters are Associated with Local Control after SBRT for Colorectal Cancer Lung Metastases. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e431-e432. DOI: 10.1016/j.ijrobp.2022.07.1640.Peer-Reviewed Original ResearchConceptsCRC lung metastasesInternal target volumeLung metastasesLocal controlPrescription dosesUnivariate analysisPrescription doseCox proportional hazards regression modelColorectal cancer lung metastasesProportional hazards regression modelsDosimetric parametersRetrospective cohort studyFavorable local controlImproved local controlLocal treatment optionsSingle cancer centerKaplan-Meier methodHazards regression modelsTarget volume dosesMATERIAL/METHODSMetastasis sizePTV D90Dosimetric predictorsMedian doseCohort studyImpact of Dosimetric Parameters on Local Control after SBRT for Pancreatic Cancer
Oh P, Laird J, Johung K. Impact of Dosimetric Parameters on Local Control after SBRT for Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e197. DOI: 10.1016/j.ijrobp.2022.07.1113.Peer-Reviewed Original ResearchConceptsStereotactic body radiotherapyInternal target volumeUnivariate regression analysisGross tumor volumeOverall survivalLocal controlPancreatic cancerPerformance statusSBRT plansTarget volumeCox proportional hazards modelDosimetric parametersAdvanced unresectable diseaseImproved local controlRetrospective cohort studyUse of chemotherapyGood local controlKaplan-Meier methodPancreatic cancer patientsTarget volume sizeProportional hazards modelHigher gross tumor volumeMATERIAL/METHODSComprehensive dosimetric analysisUnresectable diseaseAnalyzing Resident Perceptions of Current Radiation Oncology Evaluation Methods
Manjunath R, Rajeev-Kumar G, Tendulkar R, Corbin K, Johung K, Evans S, Shinohara E, Buckstein M, Pinnix C, Harkenrider M, Golden D, Hasan Y. Analyzing Resident Perceptions of Current Radiation Oncology Evaluation Methods. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e6. DOI: 10.1016/j.ijrobp.2022.06.007.Peer-Reviewed Original ResearchAltmetric
Clinical Trials
Current Trials
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033Recruiting ParticipantsPhase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma
HIC ID2000027702RolePrincipal InvestigatorPrimary Completion Date10/01/2025Recruiting ParticipantsMRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)
HIC ID2000027403RoleSub InvestigatorPrimary Completion Date11/15/2025Recruiting ParticipantsA Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC
HIC ID2000030031RoleSub InvestigatorPrimary Completion Date05/01/2028Recruiting ParticipantsPhase IB/II Trial Of Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer
HIC ID2000025868RoleSub InvestigatorPrimary Completion Date01/31/2030Recruiting Participants
Clinical Care
Overview
Kimberly L. Johung, MD, PhD, a Yale Medicine radiation oncologist, is the director of the Gastrointestinal Radiotherapy Program for Yale Cancer Center at Smilow Cancer Hospital. She is also the medical director for radiation oncology services at the Veteran Affairs Connecticut Healthcare System in West Haven, Conn.
In these roles, she treats a variety of cancers, including esophageal, gastric, pancreatic, liver, biliary, rectal, anal, and lung tumors. “What inspires me,” says Dr. Johung, “is that my job entails not only helping patients access the best care for their cancer diagnosis, but also trying to provide hope—whether it’s for a cure, a period of disease stability, alleviation of a symptom, or improved outcomes for cancer patients in the future.”
Dr. Johung is also an associate professor of therapeutic radiology at Yale School of Medicine. Her research interests include defining molecular markers, using retrospective studies, clinical trials, and translational studies, to guide treatment decisions and improve outcomes for patients with gastrointestinal malignancies.
She is a panel member for the National Comprehensive Cancer Network (Esophageal and Gastric Cancers) and is a member of the American Society for Radiation Oncology.
Clinical Specialties
Fact Sheets
Gastrointestinal Cancers
Learn More on Yale MedicineEsophageal Cancer
Learn More on Yale MedicineBrachytherapy
Learn More on Yale MedicineRadiofrequency Ablation (RFA)
Learn More on Yale Medicine
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- June 20, 2024
Chemotherapy Before Surgery Benefits Some Patients With Pancreatic Cancer
- May 24, 2024
Gastrointestinal Cancer CME Series: Gastroesophageal Cancers
- April 08, 2024
Dr. Kimberly Johung on Yale Cancer Answers
- March 28, 2024
Smilow Shares: Updates in Colorectal Cancer Screening, Diagnosis, Prevention, and Treatment
Get In Touch
Contacts
Therapeutic Radiology
P. O. Box 208040
New Haven, CT 06520-8040
United States
Locations
Smilow Cancer Hospital at Yale New Haven
Academic Office
35 Park Street, Ste LL 514
New Haven, CT 06511
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.